Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Operating Leases: 2019-2025

Historic Operating Leases for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $50.0 million.

  • Avidity Biosciences' Operating Leases rose 1215.93% to $50.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.0 million, marking a year-over-year increase of 1215.93%. This contributed to the annual value of $3.0 million for FY2024, which is 52.41% down from last year.
  • Per Avidity Biosciences' latest filing, its Operating Leases stood at $50.0 million for Q3 2025, which was up 4,029.42% from $1.2 million recorded in Q2 2025.
  • Avidity Biosciences' Operating Leases' 5-year high stood at $50.0 million during Q3 2025, with a 5-year trough of $877,000 in Q3 2021.
  • For the 3-year period, Avidity Biosciences' Operating Leases averaged around $8.8 million, with its median value being $5.4 million (2024).
  • Within the past 5 years, the most significant YoY rise in Avidity Biosciences' Operating Leases was 1,215.93% (2025), while the steepest drop was 73.79% (2025).
  • Avidity Biosciences' Operating Leases (Quarterly) stood at $10.0 million in 2021, then decreased by 23.88% to $7.6 million in 2022, then declined by 18.06% to $6.2 million in 2023, then slumped by 52.41% to $3.0 million in 2024, then soared by 1,215.93% to $50.0 million in 2025.
  • Its Operating Leases stands at $50.0 million for Q3 2025, versus $1.2 million for Q2 2025 and $2.1 million for Q1 2025.